

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate Formulation



Version 2.9      Revision Date: 10.10.2020      SDS Number: 402504-00011      Date of last issue: 13.09.2019  
Date of first issue: 07.01.2016

---

### SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Olmesartan / Amlodipine Besylate Formulation

#### **Manufacturer or supplier's details**

Company : Organon & Co.  
Address : 30 Hudson Street, 33nd floor  
Jersey City, New Jersey, U.S.A 07302  
Telephone : 551-430-6000  
Emergency telephone number : 215-631-6999  
E-mail address : EHSSTEWARD@organon.com

#### **Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical

---

### SECTION 2. HAZARDS IDENTIFICATION

#### **GHS Classification**

Reproductive toxicity : Category 1A

#### **GHS label elements**

Hazard pictograms :



Signal word : Danger

Hazard statements : H360D May damage the unborn child.

Precautionary statements :

#### **Prevention:**

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P281 Use personal protective equipment as required.

#### **Response:**

P308 + P313 IF exposed or concerned: Get medical advice/attention.

#### **Storage:**

P405 Store locked up.

#### **Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

# Olmesartan / Amlodipine Besylate Formulation

Version            Revision Date:            SDS Number:            Date of last issue: 13.09.2019  
2.9                    10.10.2020                402504-00011            Date of first issue: 07.01.2016

## Other hazards which do not result in classification

Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

## SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture            :    Mixture

### Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 30 -< 60
Olmesartan	144689-63-4	>= 10 -< 30
Amlodipine Besylate	652969-01-2	< 10
Titanium dioxide	13463-67-7	< 1

## SECTION 4. FIRST AID MEASURES

- General advice                    :    In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled                         :    If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact         :    In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact         :    In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
If easy to do, remove contact lens, if worn.  
Get medical attention.
- If swallowed                     :    If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed                    :    May damage the unborn child.  
Contact with dust can cause mechanical irritation or drying of the skin.
- Protection of first-aiders       :    First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician               :    Treat symptomatically and supportively.

## SECTION 5. FIREFIGHTING MEASURES

- Suitable extinguishing media   :    Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media   :    None known.
- Specific hazards during fire-    :    Avoid generating dust; fine dust dispersed in air in sufficient

# Olmesartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.9	10.10.2020	402504-00011	Date of first issue: 07.01.2016

---

fighting		concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

---

## SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

## SECTION 7. HANDLING AND STORAGE

Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	:	If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	:	Do not get on skin or clothing. Do not breathe dust. Do not swallow. Do not get in eyes.

## Olmesartan / Amlodipine Besylate Formulation

Version 2.9      Revision Date: 10.10.2020      SDS Number: 402504-00011      Date of last issue: 13.09.2019  
Date of first issue: 07.01.2016

- Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labelled containers.  
Store locked up.  
Keep tightly closed.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	AU OEL
	Further information: This value is for inhalable dust containing no asbestos and < 1% crystalline silica			
		TWA	10 mg/m <sup>3</sup>	ACGIH
Olmesartan	144689-63-4	TWA	30 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	300 µg/100 cm <sup>2</sup>	Internal
Amlodipine Besylate	652969-01-2	TWA	20 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	100 µg/100 cm <sup>2</sup>	Internal
Titanium dioxide	13463-67-7	TWA	10 mg/m <sup>3</sup>	AU OEL
	Further information: This value is for inhalable dust containing no asbestos and < 1% crystalline silica			
		TWA	10 mg/m <sup>3</sup> (Titanium dioxide)	ACGIH

- Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Containment technologies suitable for controlling compounds

# Olmesartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.9	10.10.2020	402504-00011	Date of first issue: 07.01.2016

---

are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
Minimize open handling.

## Personal protective equipment

Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Particulates type
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

---

## SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper	:	No data available

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate Formulation



Version 2.9      Revision Date: 10.10.2020      SDS Number: 402504-00011      Date of last issue: 13.09.2019  
Date of first issue: 07.01.2016

---

flammability limit

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity  
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle size : No data available

---

### SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

---

### SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

## Olmesartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.9	10.10.2020	402504-00011	Date of first issue: 07.01.2016

---

**Product:**

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

**Components:****Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

**Olmesartan:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
LD50 (Mouse): > 2,000 mg/kg  
LD50 (Dog): > 1,500 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

**Amlodipine Besylate:**

Acute oral toxicity : LD50 (Rat): 393 mg/kg

**Titanium dioxide:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Assessment: The substance or mixture has no acute inhalation toxicity

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Olmesartan:**

Remarks : No data available

**Titanium dioxide:**

Species : Rabbit  
Result : No skin irritation

## Olmesartan / Amlodipine Besylate Formulation

Version 2.9      Revision Date: 10.10.2020      SDS Number: 402504-00011      Date of last issue: 13.09.2019  
Date of first issue: 07.01.2016

---

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Olmesartan:**

Species : Rabbit  
Result : Moderate eye irritation  
Method : Draize Test

**Amlodipine Besylate:**

Species : Rabbit  
Result : Severe irritation

**Titanium dioxide:**

Species : Rabbit  
Result : No eye irritation

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****Olmesartan:**

Exposure routes : Skin contact  
Remarks : No data available

**Titanium dioxide:**

Test Type : Local lymph node assay (LLNA)  
Exposure routes : Skin contact  
Species : Mouse  
Result : negative

**Chronic toxicity****Germ cell mutagenicity**

Not classified based on available information.

**Components:****Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo)



# Olmesartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.9	10.10.2020	402504-00011	Date of first issue: 07.01.2016

---

cytogenetic assay)  
 Species: Mouse  
 Application Route: Ingestion  
 Result: negative

### Olmesartan:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
 Result: negative

Test Type: Mutagenicity (in vitro mammalian cytogenetic test)  
 Result: negative

Test Type: Chromosome aberration test in vitro  
 Test system: Chinese hamster lung cells  
 Result: positive

Test Type: Mouse Lymphoma  
 Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
 Species: Mouse  
 Cell type: Bone marrow  
 Application Route: Oral  
 Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

### Amlodipine Besylate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
 Result: negative

Test Type: Chromosome aberration test in vitro  
 Result: negative

### Titanium dioxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
 Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test  
 Species: Mouse  
 Result: negative

### Carcinogenicity

Not classified based on available information.

### Components:

#### Cellulose:

Species : Rat  
 Application Route : Ingestion  
 Exposure time : 72 weeks

## Olmesartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.9	10.10.2020	402504-00011	Date of first issue: 07.01.2016

---

Result : negative

**Olmesartan:**

Species : Rat  
 Application Route : Oral  
 Exposure time : 2 Years  
 Result : negative

Species : Mouse  
 Application Route : Oral  
 Exposure time : 6 Months  
 Result : negative

**Amlodipine Besylate:**

Species : Mouse  
 Application Route : Oral  
 Exposure time : 2 Years  
 Result : negative

Species : Rat  
 Application Route : Oral  
 Exposure time : 2 Years  
 Result : negative

**Titanium dioxide:**

Species : Rat  
 Application Route : inhalation (dust/mist/fume)  
 Exposure time : 2 Years  
 Method : OECD Test Guideline 453  
 Result : positive  
 Remarks : The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in inhalation studies with animals.

**Reproductive toxicity**

May damage the unborn child.

**Components:****Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

## Olmesartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.9	10.10.2020	402504-00011	Date of first issue: 07.01.2016

---

**Olmesartan:**

Effects on fertility : Test Type: Fertility  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 1,000 mg/kg body weight  
Result: No effects on fertility

Effects on foetal development : Test Type: Development  
Species: Rat  
Application Route: Oral  
Dose: 1000 milligram per kilogram  
Result: No teratogenic effects

Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Dose: 1 milligram per kilogram  
Result: No teratogenic effects

Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: LOAEL: >= 1.6 mg/kg body weight  
Symptoms: Malformations were observed., Reduced body weight  
Result: Effects on postnatal development

Reproductive toxicity - Assessment : Positive evidence of adverse effects on development from human epidemiological studies.

**Amlodipine Besylate:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Fertility: NOAEL: 10 mg/kg body weight  
Result: No effects on fertility

Test Type: Fertility/early embryonic development  
Species: Rabbit  
Application Route: Ingestion  
Fertility: NOAEL: 25 mg/kg body weight  
Result: No effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Developmental Toxicity: LOAEL: 10 mg/kg body weight  
Result: Effects on foetal development

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Ingestion  
Developmental Toxicity: NOAEL: 10 mg/kg body weight  
Result: No effects on foetal development

## Olmesartan / Amlodipine Besylate Formulation

Version            Revision Date:            SDS Number:            Date of last issue: 13.09.2019  
2.9                10.10.2020                402504-00011            Date of first issue: 07.01.2016

---

Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Ingestion  
Developmental Toxicity: LOAEL: 1.6 mg/kg body weight  
Result: Effects on foetal development  
Remarks: Maternal toxicity observed.

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

Not classified based on available information.

**Repeated dose toxicity****Components:****Cellulose:**

Species                                : Rat  
NOAEL                                 : >= 9,000 mg/kg  
Application Route                    : Ingestion  
Exposure time                        : 90 Days

**Olmesartan:**

Species                                : Rat  
NOAEL                                 : 2,000 mg/kg  
Application Route                    : Oral  
Exposure time                        : 24 Months  
Remarks                               : No significant adverse effects were reported

**Amlodipine Besylate:**

Species                                : Rat  
NOAEL                                 : 15 mg/kg  
Application Route                    : Oral  
Exposure time                        : 90 d  
Remarks                               : No significant adverse effects were reported

**Titanium dioxide:**

Species                                : Rat  
NOAEL                                 : 24,000 mg/kg  
Application Route                    : Ingestion  
Exposure time                        : 28 Days

Species                                : Rat  
NOAEL                                 : 10 mg/m<sup>3</sup>  
Application Route                    : inhalation (dust/mist/fume)  
Exposure time                        : 2 yr

**Aspiration toxicity**

Not classified based on available information.

## Olmesartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.9	10.10.2020	402504-00011	Date of first issue: 07.01.2016

---

**Experience with human exposure****Product:**

Ingestion : Symptoms: Fatigue, Dizziness, Headache, Nausea

**Components:****Olmesartan:**

Eye contact : Symptoms: Eye irritation  
 Ingestion : Symptoms: hypotension  
 Remarks: May cause harm to the unborn child.  
 Based on Human Evidence

**Amlodipine Besylate:**

Eye contact : Symptoms: Severe irritation  
 Ingestion : Symptoms: Nausea, Abdominal pain, Fatigue, Headache,  
 Oedema, Palpitation

---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Cellulose:**

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l  
 Exposure time: 48 h  
 Remarks: Based on data from similar materials

**Amlodipine Besylate:**

Toxicity to fish : LC50 (*Pimephales promelas* (fathead minnow)): 2.7 mg/l  
 Exposure time: 96 h

Toxicity to daphnia and other : EC50 (*Daphnia magna* (Water flea)): 3.2 mg/l  
 aquatic invertebrates Exposure time: 48 h

Toxicity to algae/aquatic : IC50 (*Pseudokirchneriella subcapitata* (green algae)): 5.6 mg/l  
 plants Exposure time: 72 h  
 Method: OECD Test Guideline 201

**Titanium dioxide:**

Toxicity to fish : LC50 (*Oncorhynchus mykiss* (rainbow trout)): > 100 mg/l  
 Exposure time: 96 h  
 Method: OECD Test Guideline 203

Toxicity to daphnia and other : EC50 (*Daphnia magna* (Water flea)): > 100 mg/l  
 aquatic invertebrates Exposure time: 48 h

Toxicity to algae/aquatic : EC50 (*Skeletonema costatum* (marine diatom)): > 10,000 mg/l  
 plants Exposure time: 72 h

Toxicity to microorganisms : EC50: > 1,000 mg/l  
 Exposure time: 3 h  
 Method: OECD Test Guideline 209

Version 2.9      Revision Date: 10.10.2020      SDS Number: 402504-00011      Date of last issue: 13.09.2019  
Date of first issue: 07.01.2016

---

### Persistence and degradability

#### Components:

##### Cellulose:

Biodegradability : Result: Readily biodegradable.

### Bioaccumulative potential

#### Components:

##### Amlodipine Besylate:

Partition coefficient: n-octanol/water : log Pow: 3

##### Mobility in soil

No data available

##### Other adverse effects

No data available

---

## SECTION 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## SECTION 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

Not regulated as a dangerous good

#### IATA-DGR

Not regulated as a dangerous good

#### IMDG-Code

Not regulated as a dangerous good

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### National Regulations

#### ADG

Not regulated as a dangerous good

---

## SECTION 15. REGULATORY INFORMATION

**Safety, health and environmental regulations/legislation specific for the substance or mixture**

# Olmesartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.9	10.10.2020	402504-00011	Date of first issue: 07.01.2016

---

Prohibition/Licensing Requirements : There is no applicable prohibition, authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regulations.

**The components of this product are reported in the following inventories:**

AICS	: not determined
DSL	: not determined
IECSC	: not determined

---

## SECTION 16. OTHER INFORMATION

### Further information

Revision Date	: 10.10.2020
Sources of key data used to compile the Safety Data Sheet	: Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <a href="http://echa.europa.eu/">http://echa.europa.eu/</a>

Date format	: dd.mm.yyyy
-------------	--------------

### Full text of other abbreviations

ACGIH	: USA. ACGIH Threshold Limit Values (TLV)
AU OEL	: Australia. Workplace Exposure Standards for Airborne Contaminants.

ACGIH / TWA	: 8-hour, time-weighted average
AU OEL / TWA	: Exposure standard - time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New

# SAFETY DATA SHEET



## Olmesartan / Amlodipine Besylate Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.9	10.10.2020	402504-00011	Date of first issue: 07.01.2016

---

Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN